Targeting BCL‐xL‐/BCL‐2 could sensitize tumour‐resistant cells to EGFR inhibitors,21 or result in the inhibition of actin remodelling molecules counteracting adaptive resistance to BRAF inhibitors in melanoma.59 This evidence concerns the gene BCL2L1 and melanoma.